Considering that patients with constitutively activating KRAS mutations have worse prognosis across multiple tumor types including colorectal cancer [32], with worse overall survival in rectal cancer patients [33], the predominance of KRAS mutations among poor responders may reflect an intrinsic resistance to standard treatments. The gene discussed is KRAS; the disease is rectal cancer.